Additionally, in another study, researchers suggested that KRAS mutation was an independent predictor of worse overall survival in patients with lung adenocarcinoma treated with first line pembrolizumab monotherapy [27]. The gene discussed is KRAS; the disease is lung adenocarcinoma.